Purchase this article with an account.
C. Pruente, S. Sacu, B. Pemp, G. Matt, G. Weigert, G. Garhöfer, U. Schmidt-Erfurth, L. Schmetterer; Response of Retinal Vessels to Anti Vascular Endothelial Growth Factor Treatment in Patients With Branch Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3567.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
It has previously been shown that anti vascular endothelial growth factor (VEGF) treatment may reduce retinal vessel diameters and retinal blood flow in patients with age-related macular degeneration. In the present study we hypothesized that ranibizumab (lucentis 0.05ml) treatments may also reduce retinal vessel diameters and retinal blood velocities in patients with branch retinal vein occlusion (BRVO).
30 patients with clinically significant macular edema secondary to BRVO were included. The duration of the study was 3 months. Subjects were studied before, and 1 week, 1 month, 2 months and 3 months after the first ranibizumab injection. Depending on the clinical requirements up to 3 lucentis injections were administered. Retinal vessel diameters were measured using a Retinal Vessel Analzyer. Flow velocities in the retrobulbar central retinal artery (CRA) were measured using Color Doppler Imaging. Best corrected visual acuity was assessed using ETDRS charts. Measurements were done in the affected as well as in the contralateral eye.
Three patients were lost for follow up. In the remaining 27 patients we observed a significant vasoconstriction in retinal veins (p < 0.001 versus baseline) and in retinal arteries (p = 0.001 versus baseline) of the affected eyes. In addition, we observed a significant reduction in flow velocities in the BRVO eyes over time (peak systolic velocity: p = 0.041, end diastolic velocity: p = 0.017). The reduction in retinal vessel diameters and flow velocities did not correlate with changes in visual acuity or number of retreatments. In the contralateral eyes no change in retinal blood flow parameters was seen.
Branch retinal vein occlusion is an ischemic retinal disease. Given that lucentis treatment reduces retinal perfusion in these eyes the potential long-term effects of this vasoconstriction need to be considered.
Clinical Trial: :
This PDF is available to Subscribers Only